219 related articles for article (PubMed ID: 25398950)
1. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.
Johnson-Kerner BL; Ahmad FS; Diaz AG; Greene JP; Gray SJ; Samulski RJ; Chung WK; Van Coster R; Maertens P; Noggle SA; Henderson CE; Wichterle H
Hum Mol Genet; 2015 Mar; 24(5):1420-31. PubMed ID: 25398950
[TBL] [Abstract][Full Text] [Related]
2. A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization.
Nath B; Julien JP
J Neurosci; 2023 May; 43(22):4174-4189. PubMed ID: 37137704
[TBL] [Abstract][Full Text] [Related]
3. Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A.
Nath B; Phaneuf D; Julien JP
Neurotherapeutics; 2023 Jul; 20(4):1215-1228. PubMed ID: 37268847
[TBL] [Abstract][Full Text] [Related]
4. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.
Mussche S; Devreese B; Nagabhushan Kalburgi S; Bachaboina L; Fox JC; Shih HJ; Van Coster R; Samulski RJ; Gray SJ
Hum Gene Ther; 2013 Feb; 24(2):209-19. PubMed ID: 23316953
[TBL] [Abstract][Full Text] [Related]
5. Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.
Israeli E; Dryanovski DI; Schumacker PT; Chandel NS; Singer JD; Julien JP; Goldman RD; Opal P
Hum Mol Genet; 2016 Jun; 25(11):2143-2157. PubMed ID: 27000625
[TBL] [Abstract][Full Text] [Related]
6. Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
Lowery J; Jain N; Kuczmarski ER; Mahammad S; Goldman A; Gelfand VI; Opal P; Goldman RD
Mol Biol Cell; 2016 Feb; 27(4):608-16. PubMed ID: 26700320
[TBL] [Abstract][Full Text] [Related]
7. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Mahammad S; Murthy SN; Didonna A; Grin B; Israeli E; Perrot R; Bomont P; Julien JP; Kuczmarski E; Opal P; Goldman RD
J Clin Invest; 2013 May; 123(5):1964-75. PubMed ID: 23585478
[TBL] [Abstract][Full Text] [Related]
8. Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis.
Johnson-Kerner BL; Roth L; Greene JP; Wichterle H; Sproule DM
Muscle Nerve; 2014 Oct; 50(4):467-76. PubMed ID: 24947478
[TBL] [Abstract][Full Text] [Related]
9. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.
Boizot A; Talmat-Amar Y; Morrogh D; Kuntz NL; Halbert C; Chabrol B; Houlden H; Stojkovic T; Schulman BA; Rautenstrauss B; Bomont P
Acta Neuropathol Commun; 2014 Apr; 2():47. PubMed ID: 24758703
[TBL] [Abstract][Full Text] [Related]
10. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.
Kang JJ; Liu IY; Wang MB; Srivatsan ES
Hum Genet; 2016 Jul; 135(7):675-84. PubMed ID: 27023907
[TBL] [Abstract][Full Text] [Related]
11. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment.
Chen PH; Hu J; Wu J; Huynh DT; Smith TJ; Pan S; Bisnett BJ; Smith AB; Lu A; Condon BM; Chi JT; Boyce M
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31944090
[TBL] [Abstract][Full Text] [Related]
12. Gigaxonin is required for intermediate filament transport.
Renganathan B; Zewe JP; Cheng Y; Paumier JM; Kittisopikul M; Ridge KM; Opal P; Gelfand VI
FASEB J; 2023 May; 37(5):e22886. PubMed ID: 37043392
[TBL] [Abstract][Full Text] [Related]
13. Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1.
Dequen F; Bomont P; Gowing G; Cleveland DW; Julien JP
J Neurochem; 2008 Oct; 107(1):253-64. PubMed ID: 18680552
[TBL] [Abstract][Full Text] [Related]
14. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.
Bomont P; Cavalier L; Blondeau F; Ben Hamida C; Belal S; Tazir M; Demir E; Topaloglu H; Korinthenberg R; Tüysüz B; Landrieu P; Hentati F; Koenig M
Nat Genet; 2000 Nov; 26(3):370-4. PubMed ID: 11062483
[TBL] [Abstract][Full Text] [Related]
15. Giant axonal neuropathy.
Hentati F; Hentati E; Amouri R
Handb Clin Neurol; 2013; 115():933-8. PubMed ID: 23931822
[TBL] [Abstract][Full Text] [Related]
16. The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.
Lin NH; Huang YS; Opal P; Goldman RD; Messing A; Perng MD
Mol Biol Cell; 2016 Dec; 27(25):3980-3990. PubMed ID: 27798231
[TBL] [Abstract][Full Text] [Related]
17. Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.
Johnson-Kerner BL; Garcia Diaz A; Ekins S; Wichterle H
PLoS One; 2015; 10(10):e0140157. PubMed ID: 26460568
[TBL] [Abstract][Full Text] [Related]
18. The CRL3
Park HM; Le L; Nguyen TT; Nam KH; Ordureau A; Lee JE; Nguyen TV
Proc Natl Acad Sci U S A; 2023 Nov; 120(45):e2306395120. PubMed ID: 37903270
[TBL] [Abstract][Full Text] [Related]
19. Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
Bomont P; Koenig M
Hum Mol Genet; 2003 Apr; 12(8):813-22. PubMed ID: 12668605
[TBL] [Abstract][Full Text] [Related]
20. Giant axonal neuropathy caused by a novel compound heterozygous mutation in the gigaxonin gene.
Xu M; Da YW; Liu L; Wang F; Jia JP
J Child Neurol; 2013 Oct; 28(10):1316-9. PubMed ID: 23248352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
